Top

Supportive Care in Cancer

Published in:

01-02-2015 | Original Article

Reproductive health and endocrine disruption in women with breast cancer: a pilot study

Authors: Ashlesha Patel, Alicia Roston, Almae Uy, Erika Radeke, Arden Roston, Louis Keith, H. A. Zaren

Published in: Supportive Care in Cancer | Issue 2/2015

Abstract

Purpose

The purpose of this study was to assess whether incorporation of an original reproductive health assessment and algorithm into breast cancer care helps providers appropriately manage patient reproductive health goals and to follow laboratory markers for fertility and correlate these with menstruation.

Methods

This prospective observational pilot study was set in an urban, public hospital. Newly diagnosed premenopausal breast cancer patients between 18 and 49 years old were recruited for this study prior to chemotherapy initiation. As the intervention, these patients received a reproductive health assessment and care per the study algorithm at 3-month intervals for 24 months. Blood samples were also collected at the same time intervals. The main outcome measures were to assess if the reproductive health management was consistent with patient goals and to track any follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH) level changes throughout treatment and post-treatment period.

Results

Two patients were pregnant at study initiation. They received obstetric consultations, opted to continue pregnancies, and postpone treatment; both delivered at term without complications. One woman desired future childbearing and received fertility preservation counseling. All women received family planning consultations and received/continued effective contraceptive methods. Seventy-three percent used long-term contraception, 18 % remained abstinent, and 9 % used condoms. During chemotherapy, FSH rose to menopausal levels in 82 % of patients and TSH rose significantly in 9 %. While 82 % of women experienced amenorrhea, 44 % of these women resumed menstruation after chemotherapy.

Conclusions

The assessment and algorithm were useful in managing patients’ reproductive health needs. Chemotherapy-induced endocrine disruption impacted reproductive health.

American Cancer Society. Breast cancer facts & figures 2011–2012. Atlanta: American Cancer Society, Inc

Patel A, Sreedevi M, Malapati R, Sutaria R, Schoenhage MB, Patel AR et al (2009) Reproductive health assessment for women with cancer: a pilot study. Am J Obstet Gynecol 201(2):190CrossRef

Duffy CM, Allen SM, Clark MA (2005) Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol 23(4):766–73PubMedCrossRef

Thewes B, Meiser B, Rickard J, Friedlander M (2003) The fertility- and menopause-related information needs of younger women with a diagnosis of breast cancer: a qualitative study. Psychooncology 12(5):500–11PubMedCrossRef

Peate M, Meiser B, Hickey M, Friedlander M (2009) The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review. Breast Cancer Res Treat 116(2):215–23PubMedCrossRef

Patel AA, Mini S, Sutaria RP, Schoenhage MB, Patel AR, Radeke EK et al (2008) Reproductive health issues in women with cancer. J Oncol Pract 4(2):101–5PubMedCentralPubMedCrossRef

Steiner MJ, Trussell J, Johnson S (2007) Communicating contraceptive effectiveness: an updated counseling chart. Am J Obstet Gynecol 197(1):118PubMedCrossRef

Helewa M, Levesque P, Provencher D, Lea RH, Rosolowich V, Shapiro HM (2002) Breast cancer, pregnancy, and breastfeeding. J Obstet Gynaecol Can 24(2):164–80, quiz 81-4PubMed

Steinkellner A, Chen W, Denison SE (2010) Adherence to oral contraception in women on category X medications. Am J Med 123(10):929–34 e1PubMedCrossRef

10.

Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA et al (2006) Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 15(8):546–54PubMedCrossRef

11.

Finer LB, Zolna MR (2011) Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 84(5):478–85PubMedCentralPubMedCrossRef

12.

St James PJ, Younger MD, Hamilton BD, Waisbren SE (1993) Unplanned pregnancies in young women with diabetes. An analysis of psychosocial factors. Diabetes Care 16(12):1572–8PubMedCrossRef

13.

Holing EV, Beyer CS, Brown ZA, Connell FA (1998) Why don't women with diabetes plan their pregnancies? Diabetes Care 21(6):889–95PubMedCrossRef

14.

Chor J, Rankin K, Harwood B, Handler A (2011) Unintended pregnancy and postpartum contraceptive use in women with and without chronic medical disease who experienced a live birth. Contraception 84(1):57–63PubMedCrossRef

15.

Green DM, Whitton JA, Stovall M, Mertens AC, Donaldson SS, Ruymann FB et al (2002) Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol 187(4):1070–80PubMedCrossRef

16.

Winther JF, Boice JD Jr, Svendsen AL, Frederiksen K, Olsen JH (2009) Induced abortions in Danish cancer survivors: a population-based cohort study. J Natl Cancer Inst 101(9):687–9PubMedCentralPubMedCrossRef

17.

Mitwally MF (2008) Management of reproductive needs in cancer patients: clinical perspectives. Expert Rev Anticancer Ther 8(10):1589–95PubMedCrossRef

18.

Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M et al (2004) Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22(20):4174–83PubMedCrossRef

19.

Chasle S, How CC (2003) The effect of cytotoxic chemotherapy on female fertility. Eur J Oncol Nurs 7(2):91–8PubMedCrossRef

20.

Del Mastro L, Catzeddu T, Venturini M (2006) Infertility and pregnancy after breast cancer: current knowledge and future perspectives. Cancer Treat Rev 32(6):417–22PubMedCrossRef

21.

Schwarz EB, Hess R, Trussell J (2009) Contraception for cancer survivors. J Gen Intern Med 24(Suppl 2):S401–6PubMedCrossRef

22.

Byrne J, Mulvihill JJ, Myers MH, Connelly RR, Naughton MD, Krauss MR et al (1987) Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 317(21):1315–21PubMedCrossRef

23.

Cvancarova M, Samuelsen SO, Magelssen H, Fossa SD (2009) Reproduction rates after cancer treatment: experience from the Norwegian radium hospital. J Clin Oncol 27(3):334–43PubMedCrossRef

24.

Gleicher N, Weghofer A, Barad DH (2010) Anti-Mullerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril 94(7):2824–7PubMedCrossRef

25.

Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J et al (2010) Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 116(3):592–9PubMedCentralPubMedCrossRef

26.

Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Lossl K, Andersen AN (2010) Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril 94(1):156–66PubMedCrossRef

27.

Reinertsen KV, Cvancarova M, Wist E, Bjoro T, Dahl AA, Danielsen T et al (2009) Thyroid function in women after multimodal treatment for breast cancer stage II/III: comparison with controls from a population sample. Int J Radiat Oncol, Biol, Phys 75(3):764–70CrossRef

28.

Giani C, Fierabracci P, Bonacci R, Gigliotti A, Campani D, De Negri F et al (1996) Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab 81(3):990–4PubMed

Title: Reproductive health and endocrine disruption in women with breast cancer: a pilot study
Authors: Ashlesha Patel
Alicia Roston
Almae Uy
Erika Radeke
Arden Roston
Louis Keith
H. A. Zaren
Publication date: 01-02-2015
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 2/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2381-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2015

Peripherally inserted central catheters in non-hospitalized cancer patients: 5-year results of a prospective study

The Spanish version of the Body Image Scale (S-BIS): psychometric properties in a sample of breast and gynaecological cancer patients

Fertility as a priority among at-risk adolescent males newly diagnosed with cancer and their parents

Changes in medication profile among patients with advanced cancer admitted to an acute palliative care unit

Development of protocol for the management of cervical cancer symptoms in resource-constrained developing countries

Exploring the views of parents regarding dietary habits of their young cancer-surviving children

Keynote webinar | Spotlight on antibody–drug conjugates in cancer